Table 2.
The list of publications included in this meta-analysis.
| Study | Duration | Sample Size Female/Male | NLR Cut-Off Value [103/µL] |
PLR Cut-Off Value [103/µL] |
SII Cut-Off Value [103/µL] |
SIRI Cut-Off Value [103/µL] |
cfDNA Cut-Off Value [ng/mL] |
Outcome | Glioblastoma Type |
|---|---|---|---|---|---|---|---|---|---|
| Bambury 2013 [45] | 2004–2009 | 74 (19/65) | 4 | - | - | multivariate | GBM | ||
| Han 2015 [46] | 2010–2014 | 152 (57/95) | 4 | - | - | - | - | multivariate | grade IV |
| Lopes 2018 [47] | 2005–2013 | 140 (42/98) | 5 | - | - | - | - | multivariate | GBM |
| Weng 2018 [19] | 2011–2014 | 239 (108/131) | 4 | - | - | - | - | multivariate | 44% IV grade |
| Yersal 2018 [48] | 2012–2017 | 80 (41/39) | 4 | 135 | - | - | - | univariate | GBM |
| Brenner 2019 [49] | 2005–2016 | 89 (43/46) | 4 | - | - | - | - | multivariate | GBM |
| Hao 2019 [50] | 2012–2017 | 187 (71/116) | 4.1 | 228.6 | - | - | - | uni/multivariate | GBM |
| Gan 2019 [51] | 2014–2018 | 135 (48/89) | 3 | - | - | - | - | multivariate | 84% IV grade |
| Lv 2019 [14] | 2006–2018 | 192 (79/113) | 2.7 | 87 | 718 | - | - | uni/multivariate | IDH -1 mutant and wild-type |
| Bagley 2020 [52] | - | 42 (20/22) | - | - | - | - | 13.4 | multivariate | IDH 1 and 2 wild-type glioblastomas (83%) |
| Marini 2020 [53] | 2013–2019 | 124 (65/59) | 4 | 175 | - | - | - | multivariate | IDH -1 mutant (48%) and wild-type (52%) |
| Mermut 2020 [54] | 2011–2018 | 75 (28/47) | 4 | - | - | - | - | univariate | GBM |
| Bagley 2021 [55] | 2018–2020 | 62 (23/39) | - | - | - | - | 25.2 | multivariate | IDH wild-type glioblastomas |
| Besiroglu 2021 [56] | 2014–2019 | 107 (49/58) | 2.9 | 159 | 785 | - | - | multivariate | GBM |
| Clavreul 2021 [57] | 2012–2020 | 85 (20/65) | 2.42 | 180.9 | 502.39 | 2.55 | - | univariate | IDH-wildtype |
| Garrett 2021 [58] | 2013–2019 | 87 (33/54) | 5.07 | - | - | - | - | univariate | GBM |
| Jarmuzek 2022 [7] | 2004–2021 | 358 (195/163) | 4.56 | - | 2003 | 3.03 | - | multivariate | 66% IV grade |
| Pasqualetti 2022 [59] | 2010–2020 | 77 (34/43) | - | 250 | 1200 | - | - | univariate | IDH 1 and 2 wild-type glioblastomas |
| Shi 2022 [12] | 2014–2018 | 132 (105/127) | 2.54 | 158.56 | 659.1 | 1.78 | - | uni/multivariate | grade IV |
| Wang 2022 [60] | 2015–2019 | 291 (105/106) | 4.86 | - | - | 1.26 | - | multivariate | grade IV |
| Yang 2022 [61] | 2016–2019 | 187 (76/111) | 2 | 213 | - | - | - | uni/multivariate | 47% IV grade |
Abbreviations: NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SII systemic immune inflammation index, SIRI systemic inflammation response index, cfDNA cell-free DNA, GBM glioblastoma, IDH1 isocitrate dehydrogenase 1.